Table 2.
Changes in TNSS and individual symptom scores during the study period.
| Parameter | Group | Symptom Score | ||||
|---|---|---|---|---|---|---|
| 0 w | 1 w | 2 w | 3 w | 4 w | ||
| TNSS | NVP-1703 | 8.09 (0.29) | 7.62 (0.29) * | 7.16 (0.35) *** | 6.84 (0.37) *** | 6.40 (0.41) *** |
| Placebo | 7.55 (0.28) | 7.65 (0.31) | 7.13 (0.33) * | 7.15 (0.34) | 6.90 (0.36) * | |
| p-Value † | 0.033 | 0.135 | 0.031 | 0.029 | ||
| Rhinorrhea | NVP-1703 | 2.29 (0.07) | 2.09 (0.09) * | 1.99 (0.09) *** | 1.90 (0.09) *** | 1.73 (0.11) *** |
| Placebo | 2.03 (0.09) | 2.10 (0.11) | 1.90 (0.11) | 1.91 (0.11) | 1.87 (0.11) | |
| p-Value † | 0.007 | 0.149 | 0.035 | 0.007 | ||
| Nasal congestion | NVP-1703 | 2.12 (0.12) | 2.02 (0.11) | 1.87 (0.12) * | 1.87 (0.12) * | 1.71 (0.12) ** |
| Placebo | 1.95 (0.12) | 2.03 (0.12) | 1.93 (0.11) | 1.93 (0.11) | 1.85 (0.12) | |
| p-Value † | 0.077 | 0.070 | 0.097 | 0.034 | ||
| Sneezing | NVP-1703 | 1.88 (0.10) | 1.77 (0.09) | 1.69 (0.10) * | 1.57 (0.12) ** | 1.49 (0.13) ** |
| Placebo | 1.68 (0.12) | 1.78 (0.10) | 1.60 (0.11) | 1.62 (0.12) | 1.55 (0.12) | |
| p-Value † | 0.069 | 0.374 | 0.087 | 0.103 | ||
| Itching | NVP-1703 | 1.81 (0.14) | 1.74 (0.11) | 1.61 (0.12) | 1.50 (0.13) ** | 1.47 (0.13) ** |
| Placebo | 1.89 (0.12) | 1.75 (0.11) | 1.69 (0.11) * | 1.69 (0.11) * | 1.63 (0.12) * | |
| p-Value † | 0.597 | 0.955 | 0.394 | 0.641 | ||
Data are expressed as mean (SEM) for TNSS and individual symptoms. † p-value for change in symptom score from baseline between NVP-1703 and placebo groups. * p < 0.05, ** p < 0.01, *** p < 0.001 for change in symptom score from baseline within groups. TNSS, total nasal symptom score.